Resources from the same session
Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation
Presenter: Kenji Tamura
Session: Breast cancer, metastatic
Resources:
Abstract
Phase II randomised clinical study of metformin plus chemotherapy vs chemotherapy alone in HER2 negative metastatic breast cancer: final results of the MYME trial
Presenter: Alessandra Gennari
Session: Breast cancer, metastatic
Resources:
Abstract
Invited discussant abstracts LBA16, LBA17 and 224PD
Presenter: Cristina Saura
Session: Breast cancer, metastatic
Resources:
Presentation
Webcast
Invited discussant abstracts 228PD, 229PD, 230PD and 231PD
Presenter: Luis Costa
Session: Breast cancer, metastatic
Resources:
Presentation
Webcast
Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2
Presenter: Hope Rugo
Session: Breast cancer, metastatic
Resources:
Abstract
Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab
Presenter: Hope Rugo
Session: Breast cancer, metastatic
Resources:
Abstract
First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count
Presenter: Francois-Clement Bidard
Session: Breast cancer, metastatic
Resources:
Abstract
FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer
Presenter: Matthew Ellis
Session: Breast cancer, metastatic
Resources:
Abstract
Everolimus use in breast cancer patients: a population-based study
Presenter: Mariana Chavez-Macgregor
Session: Breast cancer, metastatic
Resources:
Abstract
Efficacy and safety of BCD-022, trastuzumab biosimilar candidate, compared to herceptin: Results of international multicenter randomized double blind study in patients with HER2+ mBC
Presenter: Maria Shustova
Session: Breast cancer, metastatic
Resources:
Abstract